Latest Capital Raises News

Santana Minerals advanced its Bendigo-Ophir Gold Project in New Zealand with a confirmed consent decision date, major equipment agreements, and a substantial capital raise, setting the stage for development.

Icetana AI reported a 51% year-on-year jump in annual recurring revenue to $2.6 million but faced a $1.2 million net operating cash outflow in Q3 FY26, prompting plans for a capital raise amid expected cash flow improvements.

AuKing Mining has bolstered its project portfolio with the acquisition of a Tasmanian tin and silver licence and the Malawi-based Tundulu Rare Earths Project, supported by $5 million in recent equity placements.

Celsius Resources has revealed it was not informed before Maharlika Investment Corporation assigned its loan under the Omnibus Loan and Security Agreement with Makilala Mining to an Indian firm, prompting legal and financial review.

Bio-Gene Technology is progressing critical toxicology studies for Flavocide with a targeted APVMA submission in March 2027, while forging a strategic partnership to launch Qcide insecticides in Japan by late 2026.

Sabre Resources (ASX:SBR) has secured 80% stakes in two companies holding nearly 4,000km² of highly prospective gold and copper-gold projects in the Northern Territory, including drill-ready targets analogous to the Tennant Creek Mineral Field. A heavily supported $2 million placement will fund aggressive exploration including imminent drilling.

Anagenics Limited delivered a third quarter operational performance aligned with budget following its restructuring, with cash outflows narrowing and its Bouf Haircare brand generating robust royalty revenue.

Kuniko Limited has launched a prospectus offering over 51 million new options following a $3.75 million share placement, aiming to facilitate secondary trading and potential future capital raising through option exercises.

Paradigm Biopharmaceuticals has upsized a $14 million placement and launched a $2 million SPP, boosting its cash runway to around $45 million. This capital injection supports the ongoing Phase 3 trial for knee osteoarthritis, with interim results expected in Q3 2026.

PYC Therapeutics has gained Orphan Drug Designation from the European Medicines Agency for its VP-001 candidate targeting Retinitis Pigmentosa type 11, enhancing its regulatory and commercial pathway in Europe.

Babylon Pump & Power’s shares remain suspended from ASX trading as the company delays disclosure of a material transaction and capital raising, prolonging market uncertainty beyond the initial deadline.

Island Pharmaceuticals has cleared a major regulatory hurdle with the US FDA, confirming a clinical development path for its antiviral Galidesivir under the Animal Rule. Backed by a $9 million capital raise and strategic partnerships, the company is poised for potential US government procurement and biodefence market entry.